Specific Imaging of Immune Cell Dynamics Using Novel Tracer Strategies (IMMUNE-IMAGE)
The introduction of immunotherapies have had a significant impact in the treatment of cancer and inflammatory diseases. Immunotherapies work by encouraging the body’s own immune system to attack the disease. However, they do not work consistently across all patients, and it is not well understood why.
We are proud to be a partner of the IMMUNE-IMAGE consortium. The aim of the project is to advance the use of non-invasive imaging technologies to assess the activity of immune cells, developing tracers that enable study of specific immune cells. The project involves positron emission tomography (PET) for in vivo quantitative imaging.
Antaros Medical is contributing to the project through developing the Imiomics methodology to segment and quantify total tumour burden.
The IMMUNE-IMAGE project brings together 21 partners, including academic and medical medical institutions, pharmaceutical companies, and small and medium-size enterprises (SMEs).
This project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 831514. This Joint Undertaking receives support from the European Union’s Horizon 2020 research and innovation programme and EFPIA.
Link to IMI website: https://www.imi.europa.eu/
Link to IMMUNE-IMAGE website: https://www.immune-image.eu/
Link to IMI Project Factsheet: https://www.imi.europa.eu/projects-results/project-factsheets/immune-image
IMMUNE-IMAGE consortium partners:
- Coordinator: Amsterdam UMC
- Lead: F. Hoffmann-La Roche
- Partners: Antaros Medical, Bayer, Vrije Universiteit Brussel, University of Cambridge, CEA, University Medical Center Groningen (UMCG), ImaginAb, Janssen, Lawrencium Legal, Lygature, University of Münster, Novartis, Pfizer, Takeda, Ttopstart, University of Tübingen, Vall d’Hebron Institute of Oncology (VHIO), Vall d’Hebron Institut de Recerca (VHIR), Vlaams Instituut voor Biotechnologie (VIB)